ConvaVAC Chronic
Research type
Research Study
Full title
A Study to Determine the Safety and Performance of ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in Chronic Wounds
IRAS ID
359501
Contact name
Hubert Kowalski
Contact email
Sponsor organisation
Convatec plc.
Duration of Study in the UK
0 years, 9 months, 9 days
Research summary
Chronic or hard-to-heal wounds reduce health-related quality-of-life (QoL) for the patient and pose a substantial burden on healthcare professionals (HCPs) and healthcare systems. The number of chronic/hard-to-heal wounds is rising. With a global prevalence of ~1.9 per 1,000 and 1-2% in developed countries, it is predicted that the incidence will increase with the aging population. Wound care accounts for 2–4% of healthcare expenditure in Europe and costs $28 billion per year in the United States.
A promising intervention is Negative Pressure Wound Therapy (NPWT) which aids healing e.g. by promoting granulation tissue formation; by increasing tissue blood flow and lymphatic clearance. NPWT has been found to be an effective treatment to help heal chronic, complex and infected wounds. Recently, NPWT has been recommended in the management of chronic/hard-to-heal DFUs and VLUs.
In recent years, a wide range of wound dressings containing elemental silver ions (denoted by Ag+) or Ag+ releasing compounds have been developed and have gained considerable popularity. Ag+ dressings reduce e.g. wound healing times; hospital stays and dressing change frequency.REC name
West of Scotland REC 5
REC reference
25/WS/0126
Date of REC Opinion
8 Oct 2025
REC opinion
Further Information Favourable Opinion